Global Venous Thromboembolism Therapeutics Market 2017-2021

静脈血栓塞栓症(VTE)治療の世界市場2017-2021

◆タイトル:Global Venous Thromboembolism Therapeutics Market 2017-2021
◆商品コード:IRTNTR12030
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年2月17日
◆ページ数:82
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:世界
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、静脈血栓塞栓症(VTE)治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、静脈血栓塞栓症(VTE)治療の世界市場規模及び予測、薬剤種類別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Venous Thromboembolism Therapeutic
The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.

Technavio’s analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer HealthCare
• BMS
• Boehringer Ingelheim
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

[Other prominent vendors]
• Altor Bioscience
• Armetheon
• Aspen Pharma
• BioInvent International
• eXIthera Pharmaceuticals
• Gamma Therapeutics
• GlycoMimetics
• Green Cross
• Isis Pharmaceutical
• Leo Pharma
• Pfizer
• Portola Pharmaceuticals
• ThromboGenics

[Market driver]
• Increasing surgical procedures such as hip and knee replacements.
• For a full, detailed list, view our report

[Market challenge]
• Presence of alternatives such as thrombectomy and percutaneous techniques.
• For a full, detailed list, view our report

[Market trend]
• Development of drugs for new indications.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

Market overview
Top-vendor offerings

PART 03: Market research methodology

Research methodology
Economic indicators

PART 04: Introduction

Key market highlights
Highlights

PART 05: Disease overview

Diagnosis of VTE
Treatment of VTE

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview
Five forces analysis

PART 08: Market segmentation by drug class

Factor Xa inhibitors
Direct thrombin inhibitors
Heparin
Vitamin K antagonists

PART 09: Geographical segmentation

VTE therapeutics market in Americas
VTE therapeutics market in EMEA
VTE therapeutics market in APAC

PART 10: Market drivers

Increasing adoption of NOACs
Increasing surgical procedures such as hip and knee replacements
Large patient pool coupled with growing awareness campaigns

PART 11: Impact of drivers

PART 12: Market challenges

Presence of alternatives such as thrombectomy and percutaneous techniques
Unmet needs for anticoagulant reversal agents
Extensive use of generic products

PART 13: Impact of drivers and challenges

PART 14: Market trends

Development of drugs for new indications
Growing focus on emerging economies
Patient assistance programs

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

Bayer HealthCare
BMS
Boehringer Ingelheim
Daiichi Sankyo
Johnson & Johnson
Sanofi
Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings

Exhibit 02: Types of venous thromboembolism

Exhibit 03: Pipeline analysis

Exhibit 04: Key pipeline molecules

Exhibit 05: Global VTE therapeutics market snapshot

Exhibit 06: Global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 07: Opportunity analysis in global venous thromboembolism market

Exhibit 08: Five forces analysis

Exhibit 09: Factor Xa inhibitors in global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 10: Direct thrombin inhibitors in venous thromboembolism market 2016-2021 ($ millions)

Exhibit 11: Heparin in global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 12: Vitamin K antagonists in global venous thromboembolism market 2016-2021 ($ millions)

Exhibit 13: Segmentation of global VTE therapeutics market based on geography 2016 and 2021

Exhibit 14: VTE therapeutics market revenue by geography 2016-2021 (%)

Exhibit 15: Market scenario in Americas

Exhibit 16: VTE therapeutics market in Americas 2016-2021 ($ millions)

Exhibit 17: Market scenario in EMEA

Exhibit 18: VTE therapeutics market in EMEA ($ millions)

Exhibit 19: Market scenario in APAC

Exhibit 20: Venous thromboembolism therapeutics market in APAC ($ millions)

Exhibit 21: Impact of drivers

Exhibit 22: Forcefield analysis of drivers and challenges

Exhibit 23: Impact of drivers and challenges

Exhibit 24: Competitive structure analysis of global VTE therapeutics market 2015

Exhibit 25: Competitive analysis of global VTE therapeutics market 2016

Exhibit 26: Market share analysis 2015

Exhibit 27: Market penetration of various VTE manufacturers worldwide 2016

Exhibit 28: Strategic success factors of companies in global VTE therapeutics market

Exhibit 29: Bayer HealthCare: Key highlights

Exhibit 30: Bayer HealthCare: Strength assessment

Exhibit 31: Bayer HealthCare: Strategy assessment

Exhibit 32: Bayer HealthCare: Opportunity assessment

Exhibit 33: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2013-2015 ($ billions)

Exhibit 34: BMS: Key highlights

Exhibit 35: BMS: Strength assessment

Exhibit 36: BMS: Strategy assessment

Exhibit 37: BMS: Opportunity assessment

Exhibit 38: BMS: YoY revenue and growth rate of Eliquis (outside the US) 2013-2015 ($ millions)

Exhibit 39: Geographic segmentation of Eliquis 2015

Exhibit 40: Boehringer Ingelheim: Key highlights

Exhibit 41: Boehringer Ingelheim: Strength assessment

Exhibit 42: Boehringer Ingelheim: Strategy assessment

Exhibit 43: Boehringer Ingelheim: Opportunity assessment

Exhibit 44: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (Global) 2013-2015 ($ billions)

Exhibit 45: Daiichi Sankyo: Key highlights

Exhibit 46: Daiichi Sankyo: Strength assessment

Exhibit 47: Daiichi Sankyo: Strategy assessment

Exhibit 48: Daiichi Sankyo: Opportunity assessment

Exhibit 49: Johnson & Johnson: Key highlights

Exhibit 50: Johnson & Johnson: Strength assessment

Exhibit 51: Johnson & Johnson: Strategy assessment

Exhibit 52: Johnson & Johnson: Opportunity assessment

Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Xarelto 2013-2015 ($ millions)

Exhibit 54: Sanofi: Key highlights

Exhibit 55: Sanofi: Strength assessment

Exhibit 56: Sanofi: Strategy assessment

Exhibit 57: Sanofi: Opportunity assessment

Exhibit 58: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)

Exhibit 59: Geographical segmentation of Lovenox 2015



【資料のキーワード】

静脈血栓塞栓症(VTE)、静脈血栓塞栓症治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[静脈血栓塞栓症(VTE)治療の世界市場2017-2021] (Global Venous Thromboembolism Therapeutics Market 2017-2021 / IRTNTR12030)販売に関する免責事項
[静脈血栓塞栓症(VTE)治療の世界市場2017-2021] (Global Venous Thromboembolism Therapeutics Market 2017-2021 / IRTNTR12030)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆